摘要
目的观察分析吉非替尼靶向治疗晚期肺腺癌患者(advanced lung adenocarcinoma,ALD)的临床疗效及其影响因素。方法以2016年1月—2019年12月60例ALD患者为观察分析对象,均给予吉非替尼靶向治疗,观察记录治疗后不良反应发生情况并进行分级,记录该组患者的缓解时间、疾病进展时间、总生存期、平均生存期、1年生存率,评价临床疗效,并对可能影响疗效的相关因素进行分析。结果60例晚期肺腺癌患者中完全缓解4例(6.7%)、部分缓解23例(38.3%)、稳定28例(46.7%)、疾病进展5例(8.3%),平均缓解时间(7.94±2.01)个月,5例疾病进展患者的平均进展时间为(4.74±1.52)个月,所有患者总生存期5.8~27.6个月,平均生存期(9.06±3.48)个月,1年生存率48.3%(29/60),疾病控制率为91.7%(55/60),有效率为45.0%(27/60)。对相关疗效影响因素分析可见,吉非替尼靶向治疗的有效率:基因突变型患者高于基因状态不明患者,女性患者高于男性患者(P<0.05);而年龄≥60岁与否、肺癌分期ⅢB期或Ⅳ期、1次或多次化疗均对于治疗有效率无显著影响(P>0.05)。60例患者应用吉非替尼靶向治疗的不良反应主要有皮疹(73.3%,44/60)、瘙痒(25.0%,15/60)、腹泻(21.6%,13/60)、食欲不振(8.3%,5/60)等,不良反应强度大多为Ⅰ~Ⅱ度。结论吉非替尼靶向治疗ALD临床疗效显著,不良反应较轻,在基因突变型患者、女性患者中的治疗有效率尤为突出。
Objective To observe and analyze the clinical efficacy and influencing factors of gefitinib targeting therapy for advanced lung adenocarcinoma(ALD)tissues.Methods Between January 2016 and December 2019,a total of 60 patients with ALD as analysis object,and the treatment were given gefitinib targeted therapy,recorded and classified adverse reactions after treatment in order to record this group of patients’relief time,disease progression and overall survival,the average survival period,1 year survival rate,evaluation of clinical curative effect,and related factors likely to affect the curative effect were analyzed.Results Among the 60 patients with advanced lung adenocarcinoma,4 had complete remission(6.7%),23 had partial remission(38.3%),28 had stable disease(46.7%),and 5 had progressive disease(8.3%).The mean remission time(7.94±2.01)months,the average progression time of the 5 patients with disease progression was(4.74±1.52)months,the overall survival of all patients was 5.8 to 27.6 months,the average survival time was(9.06±3.48)months,and the 1 year survival rate was 48.3%(29/60),the disease control rate was 91.7%(55/60),and the effective rate was 45.0%(27/60).The analysis of the relevant factors influencing the efficacy showed that the effective rate of gefitinib targeted therapy was:gene mutation patients were higher than those with unknown gene status,female patients were higher than male patients(P<0.05);lung cancer stageⅢB orⅣ,one or multiple chemotherapy had no significant effect on the treatment efficiency(P>0.05).The main adverse reactions of 60 patients with gefitinib targeted therapy were rash(73.3%,44/60),itching(25.0%,15/60),diarrhea(21.6%,13/60),loss of appetite(8.3%,5/60),etc.,and the intensity of adverse reactions is mostly gradeⅠtoⅡ.Conclusion Targeted gefitinib therapy for ALD has significant clinical efficacy and mild adverse reactions,especially in patients with gene mutation and female patients.
作者
郭芬
GUO Fen(Department of Oncology,North District,Suzhou MunicipalHospital,Suzhou Jiangsu 215000,China)
出处
《中国卫生标准管理》
2022年第3期78-81,共4页
China Health Standard Management
关键词
肺腺癌
吉非替尼
晚期
靶向治疗
影响因素
临床疗效
lung adenocarcinoma
gefitinib
advanced stage
targeted therapy
affecting factors
clinical curative effect
